.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
US Army
Mallinckrodt
Julphar
Baxter
Argus Health
Chubb
Daiichi Sankyo
Fish and Richardson

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Method of treating cancer
Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
Inventor(s): Bing; Nan (Research Triangle Park, NC), Briley; Linda Perry (Research Triangle Park, NC), Budde; Laura R. (Research Triangle Park, NC), Cox; Charles J. (Stevenage, GB), Spraggs; Colin F. (Stevenage, GB)
Assignee: Novartis AG (CH)
Application Number:14/634,052
Patent Claims:1. A method of treating a human for breast cancer comprising: (a) obtaining a biological sample from said human; (b) detecting whether an allelic polymorphism at HLA-DQA1*0201 is present in said biological sample; (c) determining that said human does not have an allelic polymorphism at HLA-DQA1*0201 based on detecting the absence of said allelic polymorphism in step (b); and (d) administering at least one dose of lapatinib or a pharmaceutically acceptable salt or composition thereof to said human, thereby treating the human for breast cancer.

2. The method according to claim 1, wherein lapatinib, or a pharmaceutically acceptable salt or composition thereof, is administered to said human as monotherapy.

3. The method according to claim 1, wherein said lapatinib, or a pharmaceutically acceptable salt or composition thereof, is co-administered with at least one other anti-cancer agent.

4. The method according to claim 3, wherein said at least one other anti-cancer agent is selected from the group of: trastuzumab, capecitabine, paclitaxel, carboplatin, pazopanib and letrozole.

5. The method according to claim 1, further comprising determining that said human is not DQ2.2. seropositive where DQ2.2 is not detected to be present in said human.

6. The method according to claim 1, wherein said human does not show significant elevation in alanine aminotransferase (ALT) and/or total bilirubin (TBL) after the administration of at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe Novartis AG (CH) Bing; Nan (Research Triangle Park, NC), Briley; Linda Perry (Research Triangle Park, NC), Budde; Laura R. (Research Triangle Park, NC), Cox; Charles J. (Stevenage, GB), Spraggs; Colin F. (Stevenage, GB) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2010284092Mar 08, 2012
Australia2014203270Jul 10, 2014
Australia2014203270Jun 16, 2016
Brazil112012003653Mar 22, 2016
Canada2771699Feb 24, 2011
China102770140Nov 07, 2012
Denmark2467140Sep 05, 2016
Eurasian Patent Organization201270298Dec 28, 2012
European Patent Office2467140Jun 01, 2016
European Patent Office2467140Jun 27, 2012
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Citi
Julphar
Argus Health
Fish and Richardson
Cerilliant
US Department of Justice
QuintilesIMS
Accenture
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot